Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program
Portfolio Pulse from
Tiziana Life Sciences has dosed four additional patients in its Expanded Access Program for non-active secondary progressive multiple sclerosis, using its lead candidate, intranasal foralumab.
February 18, 2025 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tiziana Life Sciences has expanded its patient dosing in the ISPPEA for non-active secondary progressive multiple sclerosis, using intranasal foralumab.
The expansion of the dosing program indicates progress in Tiziana's development of intranasal foralumab, potentially leading to positive sentiment and increased investor interest. This could positively impact TLSA's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100